1. Home
  2. PSNYW vs ALXO Comparison

PSNYW vs ALXO Comparison

Compare PSNYW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

PSNYW

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

N/A

Current Price

$3.21

Market Cap

290.5M

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.09

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSNYW
ALXO
Founded
2017
2015
Country
Sweden
United States
Employees
2547
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
290.5M
240.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PSNYW
ALXO
Price
$3.21
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
6.3K
1.0M
Earning Date
03-06-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
$2,034,261,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$79.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.41
52 Week High
$7.50
$2.66

Technical Indicators

Market Signals
Indicator
PSNYW
ALXO
Relative Strength Index (RSI) 45.82 59.42
Support Level $2.88 $1.99
Resistance Level $3.99 $2.30
Average True Range (ATR) 0.34 0.16
MACD 0.01 0.06
Stochastic Oscillator 28.44 89.52

Price Performance

Historical Comparison
PSNYW
ALXO

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: